Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.

One of biotech’s best-funded startups plans to go public, as it seeks to take its obesity portfolio into a market crowded by Eli Lilly, Novo

Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.

Merck is planning a pivotal trial for Winrevair in an uncommon kind of heart failure after seeing a “pretty profound” benefit at the lowest dose

Biogen trumpeted new Phase 2 lupus data on Saturday for a program it hopes will become a pillar of its immunology pipeline. The drug litifilimab